Managing Oligometastatic Prostate Cancer Without Lifelong Systemic Therapy скачать в хорошем качестве

Managing Oligometastatic Prostate Cancer Without Lifelong Systemic Therapy

A regional roundtable discussion, moderated by L. Crain Garrot, MD, Georgia Cancer Specialists, focused on the diagnostic and treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Garrot was joined by other Atlanta-based urologists and medical oncologists, including Shailesh Satpute, MD, PhD, Georgia Cancer Specialists; Yasin Bhanji, MD, Georgia Urology; Caroline Lu, MD, Georgia Urology; and Froylan Gonzalez, MD, Georgia Urology. In the fourth segment of the roundtable, the panel considers the evolving management of oligometastatic prostate cancer, highlighting the role of metastasis-directed therapy and next-generation imaging like PSMA PET in guiding treatment decisions. They also explore when to use or de-escalate systemic therapies, the importance of patient-specific factors, and the nuanced use of triplet therapy in younger, healthier men.